“…Although varying in detail, most studies are consistent that low E-cadherin expression correlates with increasing aggressiveness, poor differentiation, and deep myometrial invasion of the carcinoma [130,131,132,133,134,135,136,137,138,139]. In accordance, E-cadherin was found to be more often and prominently expressed in endometrioid adenocarcinoma than in serous papillary or clear cell tumors [131,139,140], and a high E-cadherin level has been associated with reduced mortality, disease progression, and disease recurrence rate and thus is associated with a better prognosis [141].…”